ClinicalTrials.gg

Program

etrasimod

Also written as “Etrasimod”, “APD334” and “Etrasimod Immediate Release (IR)”.

Its studies are mostly in Colitis, Ulcerative · Dermatitis, Atopic · Crohn Disease · Alopecia Areata · Eosinophilic Esophagitis, led by 2 companies.

Furthest: phase 3, since May 8, 201921 company-led studies, 4 open or runningNext primary completion: Jun 16, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer203 open or runningphase 3since May 8, 2019May 13, 2015Jun 16, 2029phase 2 · NCT05287126
Everstar Therapeutics11 open or runningphase 3since Nov 22, 2019Nov 22, 2019none ahead

Also a collaborator on its studies: arena-is-a-wholly-owned-subsidiary-of-pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since May 13, 2015.

  1. Jun 21, 2019Phase 3 study in Colitis, UlcerativePfizer · NCT03996369 · 354 enrolled · United States, Argentina, Australia and more
  2. Nov 12, 2019Phase 2 study in Dermatitis, AtopicPfizer · NCT04162769 · 140 enrolled · United States, Australia, Canada
  3. Nov 20, 2019Phase 3 study in Crohn DiseasePfizer · NCT04173273 · 379 enrolled · United States, Argentina, Australia and more
  4. Nov 22, 2019Everstar Therapeutics's first study: phase 3 study in Moderately to Severely Active Ulcerative ColitisNew to Everstar TherapeuticsEverstar Therapeutics · NCT04176588 · 341 enrolled · China
  5. Sep 15, 2020Phase 2 study in Alopecia AreataPfizer · NCT04556734 · 80 enrolled · United States, Canada
  6. Oct 23, 2020Phase 2 study in Colitis, UlcerativePfizer · NCT04607837 · 234 enrolled · United States, Australia, Belarus and more
  7. Dec 19, 2020Phase 2 study in Eosinophilic EsophagitisPfizer · NCT04682639 · 108 enrolled · United States, Australia, Belgium and more
  8. Jan 11, 2021Phase 3 study in Colitis, UlcerativePfizer · NCT04706793 · 42 enrolled · Japan
  9. Sep 20, 2021Phase 2 study in Colitis, UlcerativePfizer · NCT05061446 · 54 enrolled · Japan
  10. Mar 10, 2022Phase 2 study in Colitis, UlcerativePfizer · NCT05287126 · 36 planned · United States, Japan, Poland and more
  11. Dec 22, 2022Phase 3 study in Dermatitis, AtopicPfizer · NCT05732454 · 58 enrolled · United States, Canada, Czechia and more
  12. Nov 15, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT06140290 · 8 enrolled · Belgium
  13. Aug 5, 2025Phase 1 study in Healthy ParticipantPfizer · NCT07153159 · 8 enrolled · Belgium
  14. Mar 10, 2026Phase 2 study in Colitis, UlcerativePfizer · NCT07470879 · 24 planned · United States, Australia, Canada and more

Ahead

  1. Jun 16, 2029Primary completion: phase 2 study in Colitis, UlcerativePfizer · NCT05287126
  2. Jun 19, 2029Primary completion: phase 3 study in Colitis, UlcerativePfizer · NCT03950232
  3. Sep 8, 2030Primary completion: phase 2 study in Colitis, UlcerativePfizer · NCT07470879

TargetBeta

“Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor Edg-8 modulator”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
fingolimodruleNovartisphase 455

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07470879Colitis, Ulcerative · United States, Australia, Canada and more2RecruitingPfizerSep 8, 203024
NCT07153159Healthy Participant · Belgium1CompletedPfizerSep 18, 20268
NCT06140290Healthy Participants · Belgium1CompletedPfizerMar 1, 20248
NCT05732454Dermatitis, Atopic · United States, Canada, Czechia and more3TerminatedPfizerApr 29, 202458
NCT05287126Colitis, Ulcerative · United States, Japan, Poland and more2RecruitingPfizerJun 16, 202936
NCT05061446Colitis, Ulcerative · Japan2CompletedPfizerOct 6, 202354
NCT04706793Colitis, Ulcerative · Japan3CompletedPfizerAug 3, 202242
NCT04682639Eosinophilic Esophagitis · United States, Australia, Belgium and more2CompletedPfizerSep 30, 2022108
NCT04607837Colitis, Ulcerative · United States, Australia, Belarus and more2CompletedPfizerJun 19, 2024234
NCT04556734Alopecia Areata · United States, Canada2CompletedPfizerJun 7, 202380
NCT04176588Moderately to Severely Active Ulcerative Colitis · China3Active, not recruitingEverstar TherapeuticsJul 2024341
NCT04173273Crohn Disease · United States, Argentina, Australia and more3TerminatedPfizerApr 23, 2025379
NCT04162769Dermatitis, Atopic · United States, Australia, Canada2CompletedPfizerSep 9, 2020140
NCT03996369Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedPfizerDec 7, 2021354
NCT03950232Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingPfizerJun 19, 2029896
NCT03945188Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedPfizerFeb 8, 2022433
NCT03155932Liver Cirrhosis, Biliary · United States, Australia, New Zealand2TerminatedPfizerJan 31, 20192
NCT03139032Inflammatory Bowel Diseases · Belgium, Germany, Serbia2TerminatedPfizerDec 6, 20171
NCT03072953Pyoderma Gangrenosum · Australia, New Zealand2TerminatedPfizerMay 22, 20182
NCT02536404Colitis, Ulcerative · United States, Australia, Austria and more2CompletedPfizerNov 1, 2018118
NCT02447302Colitis, Ulcerative · United States, Australia, Austria and more2CompletedPfizerFeb 14, 2018156

How it is read

Names in the registry

  • “Etrasimod”, 19 entries
  • “APD334”, 3 entries
  • “etrasimod”, 1 entry
  • “Etrasimod Immediate Release (IR)”, 1 entry
  • “Etrasimod 1 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.